Automated JAK2V617F quantification using a magnetic filtration system and sequence-specific primer-single molecule fluorescence detection

Cancer Genetics and Cytogenetics

Volumn 179, Issue 1, 2007, Pages 19-24

  Ohyashiki, Kazuma ^a   Hori, Kunio ^b   Makino, Tohru ^b   Ohyashiki, Junko H ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b NovusGene Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE; JANUS KINASE 2; OLIGONUCLEOTIDE; PHENYLALANINE; THYMINE; VALINE; FLUORESCENT DYE; JAK2 PROTEIN, HUMAN; PRIMER DNA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CHRONIC DISEASE; DEVICE; DNA EXTRACTION; FILTER; FLUORESCENCE; FLUORESCENCE ACTIVATED CELL SORTING; HETEROZYGOTE; HIGH THROUGHPUT SCREENING; HOMOZYGOTE; HUMAN; INTERMETHOD COMPARISON; MAGNETIC FILTRATION SYSTEM; MAGNETISM; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SEQUENCE ANALYSIS; SEQUENCE SPECIFIC PRIMER SINGLE MOLECULE FLUORESCENCE DETECTION; FILTRATION; FLOW CYTOMETRY; GENETIC SCREENING; GENETICS; METHODOLOGY; NUCLEOTIDE SEQUENCE; PLASMID; POINT MUTATION; POLYCYTHEMIA VERA; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

DNA MUTATIONAL ANALYSIS; DNA PRIMERS; FILTRATION; FLOW CYTOMETRY; FLUORESCENT DYES; GENETIC SCREENING; HUMANS; JANUS KINASE 2; PLASMIDS; POINT MUTATION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 35548943033     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2007.07.008     Document Type: Article

References (22)

1. James C., Ugo V., Le Couédic J.-P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., and Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434 (2005) 1144-1145
2. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N., and Green A.R. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
3. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., and Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 779-790
4. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsperger J., Koo S., Lee J.C., Gabriel S., Mercher T., D'Andrea A., Frohling S., Dohner K., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.R., Meyerson M., Golub T.R., Lee S.J., and Gilliland D.G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
5. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B., and Zhao Z.J. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280 (2005) 22788-22792
6. Schafer A.I. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 107 (2006) 4214-4222
7. De Keersmaecker K., and Cools J. Chronic myeloproliferative disorders: a tyrosine kinase tale. Leukemia 20 (2006) 200-205
8. James C., Delhommeau F., Marzac C., Teyssandier I., Couedic J.P., Giraudier S., Roy L., Saulnier P., Lacroix L., Maury S., Tulliez M., Vainchenker W., Ugo V., and Casadevall N. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 20 (2006) 350-353
9. Vizmanos J.L., Ormazábal C., Larráyoz M.J., Cross N.C.P., and Calasanz M.J. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia 20 (2006) 534-535
10. Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.L., Marsden J.T., Duffy A., Boyd E.M., Bench A.J., Scott M.A., Vassiliou G.S., Milligan D.W., Smith S.R., Erber W.N., Bareford D., Wilkins B.S., Reilly J.T., Harrison C.N., Green A.R., United Kingdom Myeloproliferative Disorders Study Group, Medical Research Council Adult Leukaemia Working Party, and Australasian Leukaemia and Lymphoma Group. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366 (2005) 1945-1953
11. Wolanskyj A.P., Lasho T.L., Schwager S.M., McClure R.F., Wadleigh M., Lee S.J., Gilliland D.G., and Tefferi A. JAK2 mutation in essential thrombocythemia: clinical associations and long-term prognostic relevance. Br J Haematol 131 (2005) 208-213
12. Antonioli E., Guglielmelli P., Pancrazzi A., Bogani C., Verrucci M., Ponziani V., Longo G., Bosi A., and Vannucchi A.M. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19 (2005) 1847-1849
13. Jones A.V., Kreil S., Zoi K., Waghorn K., Curtis C., Zhang L., Score J., Seear R., Chase A.J., Grand F.H., White H., Zoi C., Loukopoulos D., Terpos E., Vervessou E.C., Schultheis B., Emig M., Ernst T., Lengfelder E., Hehlmann R., Hochhaus A., Oscier D., Silver R.T., Reiter A., and Cross N.C. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
14. Vannucchi A.M., Pancrazzi A., Bogani C., Antonioli E., and Gugliemlli P. A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 20 (2006) 1055-1060
15. Obata K., Segawa O., Yakabe M., Ishida Y., Kuroita T., Ikeda K., Kawakami B., Kawamura Y., Yohda M., Matsunaga T., and Tajima H. Development of a novel method for operation magnetic particles, migration technology, and its use for automating nucleic acid purification. J Biosci Bioengineer 91 (2001) 500-503
16. Bannai M., Higuchi K., and Akesaki T. Single-nucleotide-polymorphism genotyping for whole-genome-amplified samples using automated fluorescence correlation spectroscopy. Ann Biochem 327 (2004) 215-221
17. Ohyashiki K., Aota Y., Akahane D., Gotoh A., Miyazawa K., Kimura Y., and Ohyashiki J.H. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndrome (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 19 (2005) 2359-2360
18. V617F-positive chronic myeloproliferative disorders: semi-quantitative analysis of mutated allele by sequence-specific primer-single molecule fluorescence detection assay. Leukemia 21 (2007) 1097-1099
19. V617Fmutation: a single institutional study in Japan. Leukemia 21 (2007) 1570-1571
20. Poodt J., Fijnheer R., Walsh I., and Hermans M. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood. Hematol Oncol 24 (2006) 227-233
21. Lay M., Mariappan R., Gotlib J., Dietz L., Sebastian S., Schrijver I., and Zehnder J.L. Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. J Mol Diagn 8 (2006) 330-334
22. Verstovsek S., Silver R.T., Cross C.P., and Tefferi A. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?. Leukemia 20 (2006) 2067